Rapid Medical™ Gains Approval in China for the World’s Only Adjustable Thrombectomy Device
31.8.2023 19:05:00 EEST | Business Wire | Press release
Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval for its TIGERTRIEVER revascularization device. With this milestone of National Medical Product Administration (NMPA) approval, TIGERTRIEVER becomes the first device to offer patient-specific solutions for removing blood clots from the brain to advance the treatment of ischemic stroke.
“This new approval for TIGERTRIEVER propels treatment for ischemic stroke patients in China,” says Ronen Eckhouse, co-founder and CEO at Rapid Medical. “We are fortunate to have an excellent partner with MicroPort Scientific Corporation, who understand the need to expand neurointerventional capabilities and individualized stroke care for these patients.”
TIGERTRIEVER technology, fueled by advancements in aerospace engineering, enables precise control during mechanical thrombectomy. Its unique operation changes these procedures from a passive to an active approach that accelerates clot capture and potentially reduces the risk of vascular injury during removal. Comparable, leading stent retrievers are self-expanding and static, which can lead to suboptimal clot removal and minimal vessel protection.
Published clinical studies demonstrate superiority to conventional stent retrievers. The results of the TIGER multicenter trial presented 3 statistically significant improvements– in restoring blood flow to the brain, good clinical outcomes, and reducing emboli to new territory–compared to an average from six pivotal stent retriever trials.1 Additionally, the TIGER trial showed fast procedure times, on par with aspiration alone2, driven by a very high rate of first-pass success.
“The successful launch of TIGERTRIEVER in China represents another stroke intervention innovation that can be applied in the real world, introducing the concept of tailored thrombectomy using an adjustable stent retriever that allows physicians to navigate procedures and unexpected circumstances with added control,” said Zhiyong Xie, President at MicroPort NeuroTech. “TIGERTRIEVER provides Chinese physicians with a new choice of neurological intervention medical devices that will benefit more patients.”
About Rapid Medical
Rapid Medical holds an exclusive distribution agreement with MicroPort NeuroTech, a subsidiary of MicroPort Scientific Corporation headquartered in China. Rapid Medical pioneers advanced interventional devices to treat neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing proprietary manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the anatomy and tailor the approach to every patient for better procedural outcomes. TIGERTRIEVER™ 13, 17 and 21, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER XL is also CE marked. More information is available at www.rapid-medical.com
______________________
1 Gupta, Rishi et al. “New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke: Primary Results of the Multicenter TIGER Trial.” Stroke vol. 52,5 (2021): 1534-1544. doi:10.1161/STROKEAHA.121.034436
2 Turk, Aquilla S 3rd et al. “Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial.” Lancet (London, England)vol. 393,10175 (2019): 998-1008. doi:10.1016/S0140-6736(19)30297-1
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831008728/en/
Contact information
Ronen Eckhouse
+972-72-2503331
ronen@rapid-medical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 15:03:00 EEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 14:00:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26 (p=0.0603). For the key secondary endpoint, Clinical Global Impression – Severity (CGI-S-ADP), the 60 mg dose achieved a change from baseline of -1.3 versus a change of -0.9 for placebo at week 6, yielding a standardized effect size of 0.37 [p=0.0077 (nominal)]. On both efficacy measures, the difference in the 60 mg dose versus placebo increased through the 6-week treatment period. The 30 mg dose showe
Arthur D. Little GEMRIX 2026 Report: The EV TRANSITION is Now an Ecosystem Race, With China Setting the Global Pace24.9.2026 13:15:00 EEST | Press release
Ecosystem, not vehicle technology is now decisive in electric vehicle (EV) adoption, and is responsible for sharp differences between markets. This is the key finding of Arthur D. Little (ADL)'s 2026 Global Electric Mobility Readiness Index (GEMRIX), which shows where ecosystems are ready and where structural gaps hold EVs back. China and Norway have both passed the point where EVs have achieved parity with internal combustion engine (ICE) vehicles. The most comprehensive study of its kind, the third edition of GEMRIX assesses 31 markets across five dimensions: macro factors, EV market/competition, customer readiness, public charging infrastructure, total cost of ownership and regulation. A score of 100 indicates broad market-readiness parity between EVs and ICE vehicles. The study highlights three global conclusions: A small group has pulled ahead. China (106) and Norway (103) are the only markets above 100; Singapore (96) and the Netherlands (90) follow closely. Sustained adoption co
Hytera Launches DIB-R6 SMART to Simplify TETRA Infrastructure and Enable Flexible Capacity Scaling24.9.2026 12:50:00 EEST | Press release
Hytera Communications, a leading global provider of critical communications technologies and solutions, announced the launch of the DIB-R6 SMART, a next-generation TETRA Digital Integrated Base Station. Engineered to simplify deployment and reduce the total cost of ownership (TCO) of mission-critical networks, it combines a multi-carrier Software-Defined Radio (SDR) architecture with operational reliability and multi-layer security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923810257/en/ Hytera DIB-R6 SMART TETRA Digital Integrated Base Station "Critical communications cannot afford the luxury of downtime, nor should operators be constrained by rigid, overweight legacy hardware," said Calvin Wang, Vice President of Hytera. "By combining enterprise-grade TETRA capacity with built-in redundancy in an all-in-one design, the DIB-R6 SMART gives operators the flexibility to scale capacity on demand and deploy across enviro
MVC Group Acquires Tailfin, Entering the Premium Bikepacking Sector24.9.2026 11:30:00 EEST | Press release
MVC Group, a group specialising in technical apparel for cycling and outdoor sports, announces the acquisition of Tailfin, the global leader in the premium technical bikepacking segment. Founded in Bristol in 2017 by Nick Broadbent – CEO, mechanical engineer and product designer – Tailfin has rapidly established itself as a leading international name in premium bikepacking bags, racks and accessories, combining design and performance with a strong focus on innovation. The company has developed proprietarytechnologies protected by more than 20 granted and pending patents, building a leading position based on engineering excellence, materials research and rigorous product development and validation processes. Over the past five years, Tailfin has achieved average annual growth of approximately 50%, reaching almost €10 million in revenues in 2025 across global markets. More than half of its revenues were generated in the US, UK and Germany, as the company progressively expanded its intern
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom